Citation Spotlight: RD-PIIINP-Hu

Human Procollagen III N-Terminal Propeptide (PIIINP) ELISA Kit Utilized in Groundbreaking COVID-19 ARDS Research

Our Human Procollagen III N-Terminal Propeptide (PIIINP) ELISA Kit, RD-PIIINP-Hu, played a crucial role in a significant study investigating the long-term effects of COVID-19-related acute respiratory distress syndrome (ARDS). This study, the first of its kind, explored the relationship between alveolar fibroproliferative response (FPR) and both mortality and long-term outcomes in COVID-19 ARDS patients.

Researchers conducted a prospective cohort study involving 154 patients. They collected bronchoalveolar lavage (BAL) and blood samples to measure 17 pulmonary fibrosis biomarkers, including NT-PCP-III, a validated marker for FPR in ARDS. By evaluating pulmonary function and chest CT scans at 3 and 12 months post-discharge, they aimed to understand the dynamic changes in alveolar FPR and their association with patient outcomes.

Key findings from the study included:

• A longitudinal increase in NT-PCP-III levels was strongly associated with increased mortality (HR 2.89, 95% CI: 2.55–3.28; P < 0.001).
• Pulmonary function showed significant improvement one year after hospital discharge, despite initial impairments.
• No strong evidence linked alveolar FPR during hospitalization to long-term pulmonary fibrosis in survivors.

This study underscores the importance of monitoring FPR in COVID-19 ARDS patients and highlights the critical role of our PIIINP ELISA Kit in advancing understanding of this condition.

View the rest of the article here: https://doi.org/10.1152/ajplung.00156.2023